We here suggest that improving maturation and lysosomal function of cathepsins by boosting their lysosomal transport in an ykt6-dependent manner, might have a therapeutic potential to lower αSyn level in PD and other synucleinopathies (see graphical abstract). The gene discussed is YKT6; the disease is Parkinson disease.